# A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

> **NCT07202546** · PHASE2 · RECRUITING · sponsor: **ViiV Healthcare** · enrollment: 150 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** VH4524184
- **DRUG:** Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets
- **DRUG:** Dolutegravir / Lamivudine (DTG/3TC)

## Key facts

- **NCT ID:** NCT07202546
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-11
- **Primary completion:** 2027-07-26
- **Final completion:** 2028-07-24
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07202546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07202546, "A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07202546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*